TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells.

Kayla A HolderKimberley BurtMichael D Grant

Published in: Clinical & translational immunology (2021)

Blocking TIGIT may be an effective strategy to invigorate antibody-dependent NK cell activity against HIV-1 activated in cellular reservoirs for cure or treatment strategies.

Keyphrases

nk cells
hiv infected
antiretroviral therapy
human immunodeficiency virus
hiv positive
bone marrow
hepatitis c virus
hiv testing
stem cells
mesenchymal stem cells